Accordingly, in addition to its own anti-cancer activities (Kidger et al., 2018), pharmacological ERK1/2 inhibition may be a viable strategy to broadly decrease IL-6 production upon DNA damage, while retaining the anti-proliferative effects of the pathway, seen in MG-63 cells. Here, IL6 is linked to cancer.